Literature DB >> 12042769

The fundamental role of epigenetic events in cancer.

Peter A Jones1, Stephen B Baylin.   

Abstract

Patterns of DNA methylation and chromatin structure are profoundly altered in neoplasia and include genome-wide losses of, and regional gains in, DNA methylation. The recent explosion in our knowledge of how chromatin organization modulates gene transcription has further highlighted the importance of epigenetic mechanisms in the initiation and progression of human cancer. These epigenetic changes -- in particular, aberrant promoter hypermethylation that is associated with inappropriate gene silencing -- affect virtually every step in tumour progression. In this review, we discuss these epigenetic events and the molecular alterations that might cause them and/or underlie altered gene expression in cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12042769     DOI: 10.1038/nrg816

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  1789 in total

1.  Analysis and accurate quantification of CpG methylation by MALDI mass spectrometry.

Authors:  Jörg Tost; Philipp Schatz; Matthias Schuster; Kurt Berlin; Ivo Glynne Gut
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

2.  Global hypomethylation in hepatocellular carcinoma and its relationship to aflatoxin B(1) exposure.

Authors:  Yu-Jing Zhang; Hui-Chen Wu; Hulya Yazici; Ming-Whei Yu; Po-Huang Lee; Regina M Santella
Journal:  World J Hepatol       Date:  2012-05-27

3.  Synthesis, characterization, and evaluation of Cd[L-proline]2, a novel histone deacetylase inhibitor that induces epigenetic modification of histone deacetylase isoforms in A549 cells.

Authors:  Anusha Chidambaram; Arunachalam Sekar; Kavya S H; Ramesh Kumar Chidambaram; Kalaiarasi Arunachalam; Senthilkumar G P; Ravikumar Vilwanathan
Journal:  Invest New Drugs       Date:  2017-08-03       Impact factor: 3.850

4.  BRMS1 transcriptional repression correlates with CpG island methylation and advanced pathological stage in non-small cell lung cancer.

Authors:  Alykhan S Nagji; Yuan Liu; Edward B Stelow; George J Stukenborg; David R Jones
Journal:  J Pathol       Date:  2010-06       Impact factor: 7.996

Review 5.  Identification of driver and passenger DNA methylation in cancer by epigenomic analysis.

Authors:  Satish Kalari; Gerd P Pfeifer
Journal:  Adv Genet       Date:  2010       Impact factor: 1.944

6.  Epigenetic silencing of somatostatin in gastric cancer.

Authors:  Kaya Jackson; Mohammed Soutto; DunFa Peng; TianLing Hu; Dana Marshal; Wael El-Rifai
Journal:  Dig Dis Sci       Date:  2010-10-07       Impact factor: 3.199

7.  Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.

Authors:  Min-Li Mo; Jie Ma; Zhao Chen; Bing Wei; Hui Li; Yong Zhou; Huaiyin Shi; Bhairavi Tolani; Joy Q Jin; Hsin-Hui Tseng; Dong Shen; Yi Zhan; Jun Li; David M Jablons; Rong-Qing Zhang; Yongjun Guo; Biao He; Hai-Meng Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2014-11-04       Impact factor: 4.553

8.  DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.

Authors:  Stela S Palii; Beth O Van Emburgh; Umesh T Sankpal; Kevin D Brown; Keith D Robertson
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

9.  Green tea polyphenol epigallocatechin 3-gallate, contributes to the degradation of DNMT3A and HDAC3 in HCT 116 human colon cancer cells.

Authors:  Vondina R Moseley; Jay Morris; Rebecca W Knackstedt; Michael J Wargovich
Journal:  Anticancer Res       Date:  2013-12       Impact factor: 2.480

10.  Suppression of intestinal neoplasia by deletion of Dnmt3b.

Authors:  Haijiang Lin; Yasuhiro Yamada; Suzanne Nguyen; Heinz Linhart; Laurie Jackson-Grusby; Alexander Meissner; Konstantinos Meletis; Grace Lo; Rudolf Jaenisch
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.